Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD)

Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD)
CANNANNEW REPORT

AEF0117 is the most advanced drug candidate of the new pharmacological class, the CB1-SSi, developed by Aelis Farma. AEF0117 aims to treat disorders related to excessive cannabis use (addiction and psychosis), which are increasing significantly worldwide. The phase 2b study will investigate the efficacy of AEF0117 for the treatment of cannabis use disorders (CUD), the current medical definition of cannabis addiction. The study will be coordinated by Columbia University and conducted at 9 clinical centers in the United States. It is expected to include approximately 330 patients and provide results in 2024. BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Mnemonic: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatment for brain diseases, announces the enrollment of the 1st patient in the phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD), the current medical definition of cannabis addiction. AEF0117 is the first drug candidate of a proprietary new class of drugs developed by Aelis Farma, the Signaling Specific inhibitors of the CB1 receptor, the “CB1-SSi”. The CB1 is the principal receptor of the endocannabinoid system and one of the most expressed neurotransmitter receptors of the brain. This receptor is involved in the regulation of several brain functions, and it is also the main target of the active ingredient of cannabis, THC. CB1-SSi, by mimicking a recently discovered natural defense mechanism of the brain1 has the potential to treat various brain pathologies without disrupting normal brain functions and behavior. Dr Frances Levin, principal investigator of the study and Professor of Psychiatry at Columbia University, said: “We are delighted to initiate this phase 2b trial of AEF0117. Disorders linked to excessive cannabis use are a growing health and societal problem in Western countries. In the United States alone almost 50 million people used cannabis…

Excerpt only …
READ MORE BELOW
Source : Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD)

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.